Thomas Cannell, Sesen Bio CEO

Sesen Bio reach­es deal with in­vestor group, paving way for Caris­ma merg­er

With a new deal, Sesen Bio’s merg­er with CAR-M play­er Caris­ma Ther­a­peu­tics is fi­nal­ly get­ting the sig­nal to move for­ward.

The deal,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA